Trial Profile

The Effect of RNS60 on ALS Biomarkers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RNS 60 (Primary) ; RNS 60 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Biomarker; Pharmacodynamics
Acronyms RNS60

Most Recent Events

07 Dec 2021 According to a Revalesio media release, data presented at the ALS/MND International Symposium 2021.
07 Dec 2021 Results presented in a Revalesio Media Release.
05 Nov 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com